{"id":5692,"date":"2019-04-02T16:48:42","date_gmt":"2019-04-02T16:48:42","guid":{"rendered":"https:\/\/thepublicationplan.com\/?p=5692"},"modified":"2019-04-02T16:48:42","modified_gmt":"2019-04-02T16:48:42","slug":"should-pharmaceutical-companies-be-doing-more-to-advocate-open-access","status":"publish","type":"post","link":"https:\/\/thepublicationplan.com\/2019\/04\/02\/should-pharmaceutical-companies-be-doing-more-to-advocate-open-access\/","title":{"rendered":"Should pharmaceutical companies be doing more to advocate open access?"},"content":{"rendered":"<p><img data-recalc-dims=\"1\" loading=\"lazy\" decoding=\"async\" data-attachment-id=\"5694\" data-permalink=\"https:\/\/thepublicationplan.com\/2019\/04\/02\/should-pharmaceutical-companies-be-doing-more-to-advocate-open-access\/pharma_mandatory_open-access_featured\/\" data-orig-file=\"https:\/\/i0.wp.com\/thepublicationplan.com\/wp-content\/uploads\/2019\/04\/Pharma_mandatory_open-access_featured.jpg?fit=940%2C788&amp;ssl=1\" data-orig-size=\"940,788\" data-comments-opened=\"1\" data-image-meta=\"{&quot;aperture&quot;:&quot;0&quot;,&quot;credit&quot;:&quot;&quot;,&quot;camera&quot;:&quot;&quot;,&quot;caption&quot;:&quot;&quot;,&quot;created_timestamp&quot;:&quot;0&quot;,&quot;copyright&quot;:&quot;&quot;,&quot;focal_length&quot;:&quot;0&quot;,&quot;iso&quot;:&quot;0&quot;,&quot;shutter_speed&quot;:&quot;0&quot;,&quot;title&quot;:&quot;&quot;,&quot;orientation&quot;:&quot;0&quot;}\" data-image-title=\"Pharma_mandatory_open access_featured\" data-image-description=\"\" data-image-caption=\"\" data-medium-file=\"https:\/\/i0.wp.com\/thepublicationplan.com\/wp-content\/uploads\/2019\/04\/Pharma_mandatory_open-access_featured.jpg?fit=300%2C251&amp;ssl=1\" data-large-file=\"https:\/\/i0.wp.com\/thepublicationplan.com\/wp-content\/uploads\/2019\/04\/Pharma_mandatory_open-access_featured.jpg?fit=940%2C788&amp;ssl=1\" class=\"alignnone size-full wp-image-5694\" src=\"https:\/\/i0.wp.com\/thepublicationplan.com\/wp-content\/uploads\/2019\/04\/Pharma_mandatory_open-access_featured.jpg?resize=940%2C788&#038;ssl=1\" alt=\"Pharma_mandatory_open access_featured\" width=\"940\" height=\"788\" srcset=\"https:\/\/i0.wp.com\/thepublicationplan.com\/wp-content\/uploads\/2019\/04\/Pharma_mandatory_open-access_featured.jpg?w=940&amp;ssl=1 940w, https:\/\/i0.wp.com\/thepublicationplan.com\/wp-content\/uploads\/2019\/04\/Pharma_mandatory_open-access_featured.jpg?resize=300%2C251&amp;ssl=1 300w, https:\/\/i0.wp.com\/thepublicationplan.com\/wp-content\/uploads\/2019\/04\/Pharma_mandatory_open-access_featured.jpg?resize=768%2C644&amp;ssl=1 768w\" sizes=\"auto, (max-width: 940px) 100vw, 940px\" \/><\/p>\n<p>In an <a href=\"https:\/\/blogs.bmj.com\/bmj\/2019\/01\/25\/richard-smith-pharmaceutical-companies-follow-public-funders-of-research-in-efforts-to-reform-science-publishing\/\" target=\"_blank\" rel=\"noopener noreferrer\">article<\/a> published in <a href=\"https:\/\/www.bmj.com\/content\/bmj-opinion\" target=\"_blank\" rel=\"noopener noreferrer\">BMJ Opinion<\/a>, Richard Smith highlights that while many public bodies have mandated open access for the research they fund, the majority of pharmaceutical companies are yet to do so.<\/p>\n<p>Smith, reporting on a meeting held by <a href=\"https:\/\/openpharma.blog\/\" target=\"_blank\" rel=\"noopener noreferrer\">Open Pharma<\/a>, notes that although pharmaceutical companies fund approximately half of all biomedical research, they have been less active than public funders in using their influence to promote open access. In fact, <a href=\"https:\/\/thepublicationplan.com\/2018\/03\/01\/shire-adopts-a-mandatory-open-access-publishing-policy\/\" target=\"_blank\" rel=\"noopener noreferrer\">Shire<\/a> and <a href=\"https:\/\/www.ipsen.com\/ipsen-commits-to-making-all-its-published-scientific-research-freely-accessible-to-everyone\/\" target=\"_blank\" rel=\"noopener noreferrer\">Ipsen<\/a> are the only pharmaceutical companies to have mandated open access to their research.<\/p>\n<p>Smith notes that the majority of public funders have joined <a href=\"https:\/\/thepublicationplan.com\/2018\/09\/18\/coalition-s-is-here\/\" target=\"_blank\" rel=\"noopener noreferrer\">cOAlition S<\/a>, a consortium in support of <a href=\"https:\/\/www.coalition-s.org\/\" target=\"_blank\" rel=\"noopener noreferrer\">Plan S<\/a>, an initiative that requires all scientific publications, funded by public grants, to be open access from 2020. Smith speculates that pharmaceutical companies may be slow to join cOAlition S because they are heavily regulated and risk averse. He also suggests that pharmaceutical companies might have concerns that mandatory open access could be perceived by regulators as directly promoting products to patients. Additionally, under Plan S, research must be published under a <a href=\"https:\/\/creativecommons.org\/licenses\/\" target=\"_blank\" rel=\"noopener noreferrer\">CC-BY license<\/a>, which allows others to use licensed work for commercial purposes. In Smith\u2019s opinion many journals may not grant such licenses to pharmaceutical companies, for misplaced fear that it will result in a loss of income from the sale of reprints.<\/p>\n<p>Smith concludes by expressing his hope that more pharmaceutical companies will work with public funders in \u2018improving the publishing of science\u2019.<\/p>\n<div data-opinionstage-embed-url=\"https:\/\/www.opinionstage.com\/api\/v1\/polls\/2545041\/code.json?width=\" style=\"display: none; visibility: hidden;\"><\/div>\n<p>\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2013<\/p>\n<p>Summary by\u00a0<a href=\"http:\/\/www.aspire-scientific.com\/#team_\" target=\"_blank\" rel=\"noopener noreferrer\">Debbie Sherwood BSc<\/a>\u00a0from\u00a0<a href=\"http:\/\/www.aspire-scientific.com\/\" target=\"_blank\" rel=\"noopener noreferrer\">Aspire Scientific<\/a><\/p>\n<p>With thanks to our sponsors, <a href=\"http:\/\/www.aspire-scientific.com\/\" target=\"_blank\" rel=\"noopener noreferrer\">Aspire Scientific Ltd<\/a> and <a href=\"http:\/\/www.networkpharma.com\/\" target=\"_blank\" rel=\"noopener noreferrer\">NetworkPharma Ltd<\/a><\/p>\n<hr \/>\n","protected":false},"excerpt":{"rendered":"<p>Many public funders have mandated open access to their research and support Plan S. Should pharmaceutical companies follow suit?<\/p>\n","protected":false},"author":1,"featured_media":5693,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"advanced_seo_description":"","jetpack_seo_html_title":"","jetpack_seo_noindex":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"Should pharmaceutical companies be doing more to advocate #openaccess?  @_OpenPharma @Richard56 #PubPlan #medcomms #ISMPP #EMWA ","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_publicize_connection_overrides":[],"_wpas_customize_per_network":false},"categories":[24853],"tags":[343162528,343162437,343162493],"class_list":["post-5692","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-open-access","tag-open-access-mandates","tag-open-science","tag-plan-s","post-has-thumbnail"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/thepublicationplan.com\/wp-content\/uploads\/2019\/04\/Pharma_mandatory_open-access.jpg?fit=683%2C512&ssl=1","jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p5Yk5l-1tO","jetpack_likes_enabled":true,"jetpack-related-posts":[],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/thepublicationplan.com\/wp-json\/wp\/v2\/posts\/5692","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thepublicationplan.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thepublicationplan.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thepublicationplan.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thepublicationplan.com\/wp-json\/wp\/v2\/comments?post=5692"}],"version-history":[{"count":2,"href":"https:\/\/thepublicationplan.com\/wp-json\/wp\/v2\/posts\/5692\/revisions"}],"predecessor-version":[{"id":5696,"href":"https:\/\/thepublicationplan.com\/wp-json\/wp\/v2\/posts\/5692\/revisions\/5696"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/thepublicationplan.com\/wp-json\/wp\/v2\/media\/5693"}],"wp:attachment":[{"href":"https:\/\/thepublicationplan.com\/wp-json\/wp\/v2\/media?parent=5692"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thepublicationplan.com\/wp-json\/wp\/v2\/categories?post=5692"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thepublicationplan.com\/wp-json\/wp\/v2\/tags?post=5692"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}